TNF Pharmaceuticals (NASDAQ:TNFA – Get Free Report) and Harrow (NASDAQ:HROW – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, dividends and analyst recommendations.
Profitability
This table compares TNF Pharmaceuticals and Harrow’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| TNF Pharmaceuticals | N/A | -69.21% | -33.98% |
| Harrow | -5.57% | 19.59% | 2.26% |
Valuation and Earnings
This table compares TNF Pharmaceuticals and Harrow”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| TNF Pharmaceuticals | N/A | N/A | -$23.36 million | ($231.00) | -0.02 |
| Harrow | $272.30 million | 5.26 | -$5.14 million | ($0.41) | -93.66 |
Harrow has higher revenue and earnings than TNF Pharmaceuticals. Harrow is trading at a lower price-to-earnings ratio than TNF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for TNF Pharmaceuticals and Harrow, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| TNF Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
| Harrow | 1 | 2 | 8 | 0 | 2.64 |
Harrow has a consensus target price of $69.43, indicating a potential upside of 80.80%. Given Harrow’s stronger consensus rating and higher possible upside, analysts plainly believe Harrow is more favorable than TNF Pharmaceuticals.
Insider and Institutional Ownership
9.6% of TNF Pharmaceuticals shares are held by institutional investors. Comparatively, 72.8% of Harrow shares are held by institutional investors. 0.5% of TNF Pharmaceuticals shares are held by company insiders. Comparatively, 12.8% of Harrow shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Volatility & Risk
TNF Pharmaceuticals has a beta of 2.04, indicating that its share price is 104% more volatile than the S&P 500. Comparatively, Harrow has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500.
Summary
Harrow beats TNF Pharmaceuticals on 10 of the 13 factors compared between the two stocks.
About TNF Pharmaceuticals
TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
About Harrow
Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.
Receive News & Ratings for TNF Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TNF Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
